These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23347902)

  • 1. Myelodysplastic syndromes should been renamed as myelodysplastic neoplasms.
    Li Y; Lin P; Ge Y; Garcia-Manero G
    Leuk Res; 2013 Apr; 37(4):463-4. PubMed ID: 23347902
    [No Abstract]   [Full Text] [Related]  

  • 2. Myelodysplastic syndromes: introduction.
    Doll DC; List AF
    Semin Oncol; 1992 Feb; 19(1):1-3. PubMed ID: 1736365
    [No Abstract]   [Full Text] [Related]  

  • 3. Myelodysplastic syndromes standardized response criteria: further definition.
    Cheson BD; Bennett JM; Kantarjian H; Schiffer CA; Nimer SD; Löwenberg B; Stone RM; Mittelman M; Sanz GF; Wijermans PW; Greenberg PL
    Blood; 2001 Sep; 98(6):1985. PubMed ID: 11535540
    [No Abstract]   [Full Text] [Related]  

  • 4. The nosology of myelodysplastic syndromes.
    Sivakumaran M
    Blood; 2002 Oct; 100(8):3053; author reply3054. PubMed ID: 12382647
    [No Abstract]   [Full Text] [Related]  

  • 5. Chromosome abnormalities in the myelodysplastic syndromes.
    Heim S; Mitelman F
    Clin Haematol; 1986 Nov; 15(4):1003-21. PubMed ID: 3552345
    [No Abstract]   [Full Text] [Related]  

  • 6. The new WHO nomenclature: introduction and myeloid neoplasms.
    Rodak BF; Leclair SJ
    Clin Lab Sci; 2002; 15(1):44-54. PubMed ID: 12778956
    [No Abstract]   [Full Text] [Related]  

  • 7. [Myelodysplastic syndrome--its natural history, clinical course and diagnosis].
    Weryńska B
    Pol Tyg Lek; 1989 Oct 2-16; 44(40-42):867-71. PubMed ID: 2487939
    [No Abstract]   [Full Text] [Related]  

  • 8. Language and the clonal myeloid diseases.
    Lichtman MA
    Blood; 2002 Jan; 99(2):725-6. PubMed ID: 11799968
    [No Abstract]   [Full Text] [Related]  

  • 9. Resolution of a linguistic dilemma.
    Janković GM
    Blood; 1991 Jun; 77(12):2793-4. PubMed ID: 2043774
    [No Abstract]   [Full Text] [Related]  

  • 10. [The MIC classification].
    Woessner S; Solé F
    Sangre (Barc); 1990 Feb; 35(1):1-3. PubMed ID: 2333578
    [No Abstract]   [Full Text] [Related]  

  • 11. Critical evaluation of the World Health Organization classification of myelodysplasia and acute myeloid leukemia.
    Heaney ML; Golde DW;
    Curr Oncol Rep; 2000 Mar; 2(2):140-3. PubMed ID: 11122835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide, a thalidomide derivative, shows promise in various applications.
    Oestreicher P
    ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
    [No Abstract]   [Full Text] [Related]  

  • 13. Good riddance to the term "refractory anemia" in myelodysplastic syndromes.
    Steensma DP
    Leuk Res; 2016 Dec; 51():22-26. PubMed ID: 27776290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France).
    Maynadié M; Girodon F; Manivet-Janoray I; Mounier M; Mugneret F; Bailly F; Favre B; Caillot D; Petrella T; Flesch M; Carli PM
    Haematologica; 2011 Jan; 96(1):55-61. PubMed ID: 20971817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infections in myelodysplastic syndromes.
    Toma A; Fenaux P; Dreyfus F; Cordonnier C
    Haematologica; 2012 Oct; 97(10):1459-70. PubMed ID: 22733024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Bardet V; Wagner-Ballon O; Guy J; Morvan C; Debord C; Trimoreau F; Benayoun E; Chapuis N; Freynet N; Rossi C; Mathis S; Gourin MP; Toma A; Béné MC; Feuillard J; Guérin E; ;
    Haematologica; 2015 Apr; 100(4):472-8. PubMed ID: 25637056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.
    Girmenia C; Candoni A; Delia M; Latagliata R; Molteni A; Oliva EN; Palumbo GA; Poloni A; Salutari P; Santini V; Voso MT; Musto P
    Blood Rev; 2019 Mar; 34():16-25. PubMed ID: 30448050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
    Loiseau C; Ali A; Itzykson R
    Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy-related myeloid neoplasms following treatment with radioiodine.
    Schroeder T; Kuendgen A; Kayser S; Kröger N; Braulke F; Platzbecker U; Klärner V; Zohren F; Haase D; Stadler M; Schlenk R; Czibere AG; Bruns I; Fenk R; Gattermann N; Haas R; Kobbe G; Germing U
    Haematologica; 2012 Feb; 97(2):206-12. PubMed ID: 21993688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation induction therapy of myelodysplastic syndromes.
    Hassan HT; Rees J
    Leuk Res; 1989; 13(7):633-7. PubMed ID: 2668648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.